@article{4394817384804304a28fbf319b203a3f,
title = "Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition",
abstract = "Psychosis is common among individuals with neurocognitive disorders, is difficult to manage, and causes considerable burden and stress to patients and caregivers. Developing effective treatments is a substantial unmet medical need but research has been slowed by the need for updated consensus diagnostic criteria. To address this need, the International Psychogeriatrics Association initiated a process to develop criteria for clinical use, research, and treatment development efforts. The process included clinical, regulatory, and industry stakeholders as well as input from a global network of experts in geriatric psychiatry responding to two surveys (N = 336). Results from the consensus process confirmed that clinicians wanted elaboration of aspects of the definition proposed by Jeste and Finkel in 2000 to ensure that the criteria are applied appropriately. Based on discussions, the survey, and emerging research, criteria were revised to apply to psychosis occurring with all major and mild neurocognitive disorders. Other important changes include providing examples of hallucinations and delusions and clarifying time course, impact, and exclusionary criteria. This definition of psychosis in major and mild neurocognitive disorders can be used to advance many types of research including development of much needed pharmacologic and nonpharmacologic interventions for psychosis in patients with neurocognitive disorders.",
keywords = "Alzheimer's disease, clinical trials, delusions, diagnoses, hallucinations, major neurocognitive disorder, mild neurocognitive disorder, psychosis, therapy development",
author = "Jeffrey Cummings and Pinto, {Luiz Cortez} and Manuel Cruz and Fischer, {Corinne E.} and Gerritsen, {Debby L.} and Grossberg, {George T.} and Hwang, {Tzung Jeng} and Zahinoor Ismail and Jeste, {Dilip V.} and Raymond Koopmans and Lanctot, {Krista L.} and Raimundo Mateos and Susan Peschin and Cristina Sampaio and Debby Tsuang and Huali Wang and Kate Zhong and Bain, {Lisa J.} and Mary Sano",
note = "Funding Information: Following completion and analysis of the survey, an international expert consensus meeting was held in Lisbon, Portugal to re-examine the criteria for psychosis in AD and develop revised criteria for based on new knowledge and understanding of the condition, information derived from the survey, and the experience and perspective of those in attendance. Participants in the consensus meeting included IPA members, international attendees, biopharma industry representatives, psychosis experts, advocates, medical directors of residential facilities, regulatory experts, and members of the International Society to Advance Alzheimer's Research and Treatment NPS Professional Interest Area representing a range of disciplines and backgrounds (participants are listed as authors of this paper). Support for this meeting was provided by unrestricted grants from pharmaceutical companies; the selection of the working group, intellectual content development, and creation of this report were independent of this funding. Supporting companies did not have approval or alteration authority. Funding Information: J. Cummings has received funding for research, consultancy and advising from Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, BioXcel, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, EIP Pharma, Eisai, Foresight, Gemvax, Green Valley, Grifols, Hisun, Idorsia, Karuna, Nutricia, Orion, Otsuka, Probiodrug, ReMYND, Resverlogix, Roche, Samumed, Samus Therapeutics, Third Rock, Signant Health, Sunovion, Suven, and United Neuroscience pharmaceutical and assessment companies. J Cummings has received consultancy fees from Alzheimer Drug Discovery Foundation; stock ownership in ADAMAS, BioAsis, MedAvante, QR Pharma, and United Neuroscience; and royalty fees for copyright ownership of Neuropsychiatric Inventory. J. Cummings is supported by Keep Memory Alive (KMA); NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. G. Grossberg has received funding for consultancy from Acadia, Avanir, BioXcel and Otsuka. TJ Huang has received speaking honorariums from Janssen Pharmaceutical, Eisai Taiwan and Otsuka. Z. Ismail has received funding for research and consultancy from Janssen, Otsuka and Lundbeck. K. Lanctot has received funding for research and advising from AbbVie Canada, ICG Pharma, Otsuka and Kondor Pharma. C. Sampaio has received honorariums from vTv Therapeutics, Kyowa, Pfizer/ Lilly and Green Valley. D. Tsuang has received research grants from NIH. H. Wang has received honorariums from Eisai and Lundbeck and consulting fees from Eisai, Biogen, vTv and F. Hoffman LaRoche. K. Zhong, L. Cortez Pinto, M. Cruz, C. Fischer, D. Gerritsen, R. Koopmans, D. Jeste, R. Mateos, S. Peschin, and L.J. Bain have no disclosures to report. Publisher Copyright: {\textcopyright} 2020 The Authors",
year = "2020",
month = dec,
doi = "10.1016/j.jagp.2020.09.002",
language = "English",
volume = "28",
pages = "1256--1269",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Elsevier Inc.",
number = "12",
}